[
  {
    "ts": null,
    "headline": "Abbott Shrugs Off 'Middling' Quarter As 2025 Sales Guidance, Diabetes Tech Shine",
    "summary": "Abbott stock reversed early losses Wednesday on its strong sales outlook for 2025 and a bullish performance from its diabetes devices.",
    "url": "https://finnhub.io/api/news?id=942b4b4926897d3f4acb2464b8482cf23155eb0f0fb825794593a9650743f670",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737579823,
      "headline": "Abbott Shrugs Off 'Middling' Quarter As 2025 Sales Guidance, Diabetes Tech Shine",
      "id": 132473306,
      "image": "https://media.zenfs.com/en/ibd.com/0c7cfa430a4d81be01e97e2456cfe160",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott stock reversed early losses Wednesday on its strong sales outlook for 2025 and a bullish performance from its diabetes devices.",
      "url": "https://finnhub.io/api/news?id=942b4b4926897d3f4acb2464b8482cf23155eb0f0fb825794593a9650743f670"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market",
    "summary": "ABT delivers a strong underlying base business performance for the fourth quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=e1fbf2a6e9b196b331ad3b8ebfa889561a7c76d5a40b133af401af5d52dec607",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737571560,
      "headline": "Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market",
      "id": 132473307,
      "image": "https://media.zenfs.com/en/zacks.com/0ebf144352a95b22dfed01b36b0e82c5",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "ABT delivers a strong underlying base business performance for the fourth quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=e1fbf2a6e9b196b331ad3b8ebfa889561a7c76d5a40b133af401af5d52dec607"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript",
    "summary": "ABT earnings call for the period ending December 31, 2024.",
    "url": "https://finnhub.io/api/news?id=556c65bfe4498e4e8c01337817b1b7caaf34eb00b1e16e46c4185ca5b9b969af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737569712,
      "headline": "Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript",
      "id": 132473308,
      "image": "https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "ABT earnings call for the period ending December 31, 2024.",
      "url": "https://finnhub.io/api/news?id=556c65bfe4498e4e8c01337817b1b7caaf34eb00b1e16e46c4185ca5b9b969af"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Down on Mixed Earnings -- Health Care Roundup",
    "summary": "Health-care companies ticked down amid mixed earnings. Johnson & Johnson fell even after it unveiled financial results that beat Wall Street expectations, as investors brace for one of its...",
    "url": "https://finnhub.io/api/news?id=0cd0e137d7e17fbbed4c2a7b2a58e4554bc2b30ce982c60a57b6dfca189fed73",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737567136,
      "headline": "Health Care Down on Mixed Earnings -- Health Care Roundup",
      "id": 132444596,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Health-care companies ticked down amid mixed earnings. Johnson & Johnson fell even after it unveiled financial results that beat Wall Street expectations, as investors brace for one of its...",
      "url": "https://finnhub.io/api/news?id=0cd0e137d7e17fbbed4c2a7b2a58e4554bc2b30ce982c60a57b6dfca189fed73"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings.",
    "summary": "Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.",
    "url": "https://finnhub.io/api/news?id=33a13fce0303c3f3bda081d3681e8d58f89293155c966056de1276716ac2f7cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737564000,
      "headline": "Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings.",
      "id": 132473309,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.",
      "url": "https://finnhub.io/api/news?id=33a13fce0303c3f3bda081d3681e8d58f89293155c966056de1276716ac2f7cf"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs misses Q4 sales estimates",
    "summary": "Abbott Laboratories (ABT) reported weaker-than-expected fourth quarter sales due to weakness in its nutrition and diagnostics units. The company's full-year outlook met estimates as medical device demand is expected to continue to grow. Catalysts Hosts Seana Smith and Madison Mills discuss the company's medical device sales, which saw double-digit gains in the quarter. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
    "url": "https://finnhub.io/api/news?id=2392207eea0a405c58a9ffd947e6c2ad511ed31d0e03f18d4c963c6919216251",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737563529,
      "headline": "Abbott Labs misses Q4 sales estimates",
      "id": 132473310,
      "image": "https://s.yimg.com/ny/api/res/1.2/UceCKsS7nu6lzYT4j5qBIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/239659d0-d8de-11ef-bf7b-5709abb6e716",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) reported weaker-than-expected fourth quarter sales due to weakness in its nutrition and diagnostics units. The company's full-year outlook met estimates as medical device demand is expected to continue to grow. Catalysts Hosts Seana Smith and Madison Mills discuss the company's medical device sales, which saw double-digit gains in the quarter. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
      "url": "https://finnhub.io/api/news?id=2392207eea0a405c58a9ffd947e6c2ad511ed31d0e03f18d4c963c6919216251"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Retain PacBio Stock in Your Portfolio for Now",
    "summary": "PACB continues to deliver growth from its unique technologies amid business seasonality concerns.",
    "url": "https://finnhub.io/api/news?id=ffa1fbe36f606613a6824b8a9f2576bc804ccf74816fca34d0928c047d40e601",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737563400,
      "headline": "Here's Why You Should Retain PacBio Stock in Your Portfolio for Now",
      "id": 132473311,
      "image": "https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "PACB continues to deliver growth from its unique technologies amid business seasonality concerns.",
      "url": "https://finnhub.io/api/news?id=ffa1fbe36f606613a6824b8a9f2576bc804ccf74816fca34d0928c047d40e601"
    }
  },
  {
    "ts": null,
    "headline": "GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub",
    "summary": "GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.",
    "url": "https://finnhub.io/api/news?id=785107d8a0ba13ca7d8bc522b87c3ef3865fa6c8210b446f904ec44a7e2f3020",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737563280,
      "headline": "GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub",
      "id": 132473312,
      "image": "https://media.zenfs.com/en/zacks.com/82aa990112b541acec95ecc4c3df7065",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.",
      "url": "https://finnhub.io/api/news?id=785107d8a0ba13ca7d8bc522b87c3ef3865fa6c8210b446f904ec44a7e2f3020"
    }
  },
  {
    "ts": null,
    "headline": "Is Abbott Laboratories (ABT) Expected to Post Impressive Earnings This Week?",
    "summary": "We recently published a list of 10 Stocks Expected To Post Impressive Earnings This Week. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks expected to post impressive earnings this week. The earnings season is in full flow as we kick off the week with [â€¦]",
    "url": "https://finnhub.io/api/news?id=7d47d3d709762ac5d1b2ca235d79411ab59a59b007c3212387fc738cea3ef2da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737562389,
      "headline": "Is Abbott Laboratories (ABT) Expected to Post Impressive Earnings This Week?",
      "id": 132473313,
      "image": "https://s.yimg.com/ny/api/res/1.2/7vGULFhzAiOKG0UyIeg5.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8b4f8f18dabae8e04006be71641b541a",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Stocks Expected To Post Impressive Earnings This Week. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks expected to post impressive earnings this week. The earnings season is in full flow as we kick off the week with [â€¦]",
      "url": "https://finnhub.io/api/news?id=7d47d3d709762ac5d1b2ca235d79411ab59a59b007c3212387fc738cea3ef2da"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Fourth-Quarter Revenue Misses Views; Healthcare Firm Sees 2025 Organic Acceleration",
    "summary": "Abbott Laboratories (ABT) reported slightly slower-than-expected fourth-quarter revenue growth on We",
    "url": "https://finnhub.io/api/news?id=565baba7d027626822e43c3a645c91e22a9bde1665983f90a3944db10f546f18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737561937,
      "headline": "Abbott Fourth-Quarter Revenue Misses Views; Healthcare Firm Sees 2025 Organic Acceleration",
      "id": 132473314,
      "image": "https://media.zenfs.com/en/mt_newswires_premium_news_706/983e4a012989877f9d00cc6859264dd7",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) reported slightly slower-than-expected fourth-quarter revenue growth on We",
      "url": "https://finnhub.io/api/news?id=565baba7d027626822e43c3a645c91e22a9bde1665983f90a3944db10f546f18"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall",
    "summary": "On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business was 8.8%. Organic growth, excluding COVID-19 testing-related sales was 10.1%. Adjusted diluted earnings per share were $1.34, in line with the analyst estimates and management consensus of $1.31-$1.37, up from $1.19 a year ago. Also Read: FDA Bans Red Dye No. 3 Effective January 2027, C",
    "url": "https://finnhub.io/api/news?id=6f3cce75758ff3657abad062855593a33a69b273f328fde16e46aa881a98f238",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737559068,
      "headline": "Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall",
      "id": 132473315,
      "image": "https://media.zenfs.com/en/Benzinga/e2afa3f4e287a5d21c3cfd4a2f988926",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business was 8.8%. Organic growth, excluding COVID-19 testing-related sales was 10.1%. Adjusted diluted earnings per share were $1.34, in line with the analyst estimates and management consensus of $1.31-$1.37, up from $1.19 a year ago. Also Read: FDA Bans Red Dye No. 3 Effective January 2027, C",
      "url": "https://finnhub.io/api/news?id=6f3cce75758ff3657abad062855593a33a69b273f328fde16e46aa881a98f238"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics",
    "summary": "The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=4d2a531e0f61a652a4feef91bb935f0dd719ba14771b535e1be89b0e405b457b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737556219,
      "headline": "Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics",
      "id": 132473316,
      "image": "https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=4d2a531e0f61a652a4feef91bb935f0dd719ba14771b535e1be89b0e405b457b"
    }
  },
  {
    "ts": null,
    "headline": "Correction to Abbott Labs 4Q Sales Just Miss Estimates Article",
    "summary": "Abbott Labs on Wednesday reported net earnings of $9.23 billion, or $5.27 a share, for the three months ended Dec. 31, up from $1.59 billion, or $1.91 cents a share, a year earlier. Abbott Labs 4Q...",
    "url": "https://finnhub.io/api/news?id=dab972c0c456ec46b69aa2741bc02a300b6eb8e9fa0a546ab51b2aedeb10e4d9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737554682,
      "headline": "Correction to Abbott Labs 4Q Sales Just Miss Estimates Article",
      "id": 132443614,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott Labs on Wednesday reported net earnings of $9.23 billion, or $5.27 a share, for the three months ended Dec. 31, up from $1.59 billion, or $1.91 cents a share, a year earlier. Abbott Labs 4Q...",
      "url": "https://finnhub.io/api/news?id=dab972c0c456ec46b69aa2741bc02a300b6eb8e9fa0a546ab51b2aedeb10e4d9"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update",
    "summary": "Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update",
    "url": "https://finnhub.io/api/news?id=3e1e6bf2a5e678f156ed1cb502f0063d20b1153ec9a7779f9bb11cfc28ae430a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737553680,
      "headline": "Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update",
      "id": 132459904,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update",
      "url": "https://finnhub.io/api/news?id=3e1e6bf2a5e678f156ed1cb502f0063d20b1153ec9a7779f9bb11cfc28ae430a"
    }
  },
  {
    "ts": null,
    "headline": "Abbott (ABT) Q4 Earnings Meet Estimates",
    "summary": "Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=c8d548ec5e1eec615252e92dcdb779c95732ff73c2f4d162e101d5e080addabf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737551703,
      "headline": "Abbott (ABT) Q4 Earnings Meet Estimates",
      "id": 132473317,
      "image": "https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=c8d548ec5e1eec615252e92dcdb779c95732ff73c2f4d162e101d5e080addabf"
    }
  },
  {
    "ts": null,
    "headline": "Abbott: Q4 Earnings Snapshot",
    "summary": "The average estimate of nine analysts surveyed by Zacks Investment Research was also for earnings of $1.34 per share. The maker of infant formula, medical devices and drugs posted revenue of $10.97 billion in the period, missing Street forecasts. Eight analysts surveyed by Zacks expected $11.02 billion.",
    "url": "https://finnhub.io/api/news?id=479fde9d67b61b3f50ff22b4f39aa5133e21a2aaa1646647d08b09f2127f82c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737547920,
      "headline": "Abbott: Q4 Earnings Snapshot",
      "id": 132473318,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The average estimate of nine analysts surveyed by Zacks Investment Research was also for earnings of $1.34 per share. The maker of infant formula, medical devices and drugs posted revenue of $10.97 billion in the period, missing Street forecasts. Eight analysts surveyed by Zacks expected $11.02 billion.",
      "url": "https://finnhub.io/api/news?id=479fde9d67b61b3f50ff22b4f39aa5133e21a2aaa1646647d08b09f2127f82c4"
    }
  },
  {
    "ts": null,
    "headline": "Abbott banks on glucose monitors, new launches to ride out China, currency hit",
    "summary": "Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device launches and growing demand for its glucose monitors to offset a hit from weakness in China and a stronger dollar.  The company, which makes medical devices and also sells nutrition products such as baby formula, has seen a large boost to sales from strong demand for FreeStyle Libre - its continuous glucose monitor.  Abbott had been facing supply issues for its Libre devices and said it will meet the demand mismatch as it gets one of its manufacturing sites up and running.",
    "url": "https://finnhub.io/api/news?id=27c46f0152b9964a6887c95f6db0440e1d8954ca868a4568a4ef86b0e70ffb5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737547359,
      "headline": "Abbott banks on glucose monitors, new launches to ride out China, currency hit",
      "id": 132473319,
      "image": "https://media.zenfs.com/en/reuters-finance.com/db9aa665b4a9714ee1e4129e53d1468e",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device launches and growing demand for its glucose monitors to offset a hit from weakness in China and a stronger dollar.  The company, which makes medical devices and also sells nutrition products such as baby formula, has seen a large boost to sales from strong demand for FreeStyle Libre - its continuous glucose monitor.  Abbott had been facing supply issues for its Libre devices and said it will meet the demand mismatch as it gets one of its manufacturing sites up and running.",
      "url": "https://finnhub.io/api/news?id=27c46f0152b9964a6887c95f6db0440e1d8954ca868a4568a4ef86b0e70ffb5a"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs: Annual EPS in line with expectations",
    "summary": "Abbott Laboratories reports fourth-quarter 2024 adjusted EPS in line with expectations at $1.34, bringing the year-to-date figure to $4.67, in line with its target range of three months ago .The...",
    "url": "https://finnhub.io/api/news?id=8afdc169f0dd38abc8713751fab1c6b921b264e23673ba43fa32f03ce5dfdc07",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737533300,
      "headline": "Abbott Labs: Annual EPS in line with expectations",
      "id": 132442081,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott Laboratories reports fourth-quarter 2024 adjusted EPS in line with expectations at $1.34, bringing the year-to-date figure to $4.67, in line with its target range of three months ago .The...",
      "url": "https://finnhub.io/api/news?id=8afdc169f0dd38abc8713751fab1c6b921b264e23673ba43fa32f03ce5dfdc07"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales",
    "summary": "By Denny Jacob Abbott Laboratories posted lower-than-expected sales in its latest quarter, dented in part by diminished demand for Covid-19 testing-related products. The healthcare-products...",
    "url": "https://finnhub.io/api/news?id=9c1c34d47af85a80238be885ef7860e45d0f6a3925674308fcfa18179299b95e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737531974,
      "headline": "Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales",
      "id": 132441983,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "By Denny Jacob Abbott Laboratories posted lower-than-expected sales in its latest quarter, dented in part by diminished demand for Covid-19 testing-related products. The healthcare-products...",
      "url": "https://finnhub.io/api/news?id=9c1c34d47af85a80238be885ef7860e45d0f6a3925674308fcfa18179299b95e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott forecasts in line annual profit on medical device sales",
    "summary": "Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including...",
    "url": "https://finnhub.io/api/news?id=2a987c2fc3a41c62c1a206523b50a6e176ed45aa556c2b53a324c66d790ae7f7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737529359,
      "headline": "Abbott forecasts in line annual profit on medical device sales",
      "id": 132441764,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including...",
      "url": "https://finnhub.io/api/news?id=2a987c2fc3a41c62c1a206523b50a6e176ed45aa556c2b53a324c66d790ae7f7"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook",
    "summary": "Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billionFourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1...",
    "url": "https://finnhub.io/api/news?id=e621d5df0a9e3f907c60b9a72f875589bb818f4c3c72121dca25bb0f78e750ca",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737529275,
      "headline": "Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook",
      "id": 132441722,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billionFourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1...",
      "url": "https://finnhub.io/api/news?id=e621d5df0a9e3f907c60b9a72f875589bb818f4c3c72121dca25bb0f78e750ca"
    }
  }
]